Compare LITB & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | ACRV |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 56.5M |
| IPO Year | 2013 | 2022 |
| Metric | LITB | ACRV |
|---|---|---|
| Price | $2.68 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 8.0K | ★ 729.1K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $1.05 |
| 52 Week High | $4.17 | $5.75 |
| Indicator | LITB | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 41.92 |
| Support Level | $2.39 | $1.51 |
| Resistance Level | $2.98 | $2.47 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.46 | 17.17 |
LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.